Member reports

Reports & insights

Sample and periodic market-intelligence reports, built from NHS England secondary-care dispensing data. New editions are published here regularly — log in to read and download them.

Please log in to view reports

These reports are available to RxLens members. Logging in is free during our launch.

Log in   Create a free account
22 June 2026 Pricing Generics & shortages Secondary care · England

NHS medicine prices: what’s getting cheaper, and what’s quietly getting dearer

A worked example tracking how medicine prices move in NHS hospitals, from the public dispensing data — the price per unit of every product, start of year versus end, across the whole of England.

  • Generic and biosimilar competition cut prices hard: ticagrelor −91%, imatinib −89%, dapagliflozin −80%.
  • Shortages pushed others up just as sharply: propofol +419%, paclitaxel +87%, and basic IV fluids (saline, glucose) +90–170%.
  • Sets it against the regulator’s excessive-pricing cases (hydrocortisone, liothyronine, phenytoin) — and shows the anomaly-screening that separates real moves from data artefacts.
Read the report (PDF)

Full price-trend monitoring across the dataset is available to RxLens subscribers — see plans.

22 June 2026 Oncology Prostate cancer Secondary care · England

Prostate cancer: the £880m hormone-therapy race — Xtandi, Erleada, Nubeqa, abiraterone

A worked example covering the leading oral hormone therapies (ARPIs) for prostate cancer across NHS hospitals in England over the latest 12 months: enzalutamide (Xtandi; Astellas), apalutamide (Erleada; J&J), darolutamide (Nubeqa; Bayer) and abiraterone (Zytiga and generics).

  • An £882m four-way market: Xtandi ~45% of spend leads, ahead of Erleada (~22%), Nubeqa (~21%) and abiraterone (~12%).
  • The newer rivals are climbing fast — Nubeqa +40% in six months, Erleada +11% — while the leader is broadly flat.
  • Cheap generic abiraterone surged ~63% after the NHS widened access in early 2026 — though its low price means spend understates how many men now take it.
Read the report (PDF)

Trust-level detail and live exploration are available to RxLens subscribers — see plans.

22 June 2026 Neurology Multiple sclerosis Secondary care · England

Multiple sclerosis: the £484m B-cell race — Ocrevus, Kesimpta, Tysabri, Briumvi

A worked example covering the leading high-efficacy MS disease-modifying therapies across NHS hospitals in England over the latest 12 months: ocrelizumab (Ocrevus; Roche), ofatumumab (Kesimpta; Novartis), natalizumab (Tysabri; Biogen) and ublituximab (Briumvi; Neuraxpharm).

  • Anti-CD20 antibodies now dominate: Ocrevus ~49% of spend, Kesimpta ~39%, natalizumab ~11%.
  • Novartis’s at-home injection Kesimpta is growing fastest — up ~19% in six months — closing on Roche’s infused Ocrevus, while Tysabri declines.
  • NICE has steered the NHS to use the least expensive of the three antibodies (ublituximab, ocrelizumab, ofatumumab) — setting up direct price competition. Concentrated in major neuroscience centres.
Read the report (PDF)

Trust-level detail and live exploration are available to RxLens subscribers — see plans.

22 June 2026 Ophthalmology Anti-VEGF Secondary care · England

Retinal anti-VEGF: Eylea vs Vabysmo in the NHS’s £960m eye-injection market

A worked example covering the leading anti-VEGF injections used in NHS hospital eye services across England over the latest 12 months: aflibercept (Eylea; Bayer), faricimab (Vabysmo; Roche) and ranibizumab (Lucentis; Novartis).

  • One of the NHS’s largest single medicine markets — about £960m a year in indicative spend.
  • A near-even duopoly: Eylea ~51% of spend, Vabysmo ~43% — Roche’s newer product has climbed to within a few points of the long-standing leader.
  • Ranibizumab, now facing biosimilars, has fallen to ~6%. Adoption is broad — 100+ NHS Trusts, led by Moorfields.
Read the report (PDF)

Trust-level detail and live exploration are available to RxLens subscribers — see plans.

22 June 2026 Oncology CDK4/6 · breast cancer Secondary care · England

CDK4/6 inhibitors: the £510m breast-cancer pill race — Verzenios, Ibrance, Kisqali

A worked example covering the three CDK4/6 inhibitors used in hormone-receptor-positive breast cancer across NHS hospitals in England over the latest 12 months: abemaciclib (Verzenios; Lilly), palbociclib (Ibrance; Pfizer) and ribociclib (Kisqali; Novartis).

  • A £510m three-way race: Verzenios ~47% of spend, Ibrance ~32%, Kisqali ~21%.
  • The first-to-market product (Ibrance) has been overtaken; Verzenios now leads, helped by its early-breast-cancer indication.
  • Kisqali is growing fastest — up ~38% in six months — tracking its July 2025 NICE expansion into high-risk early breast cancer. Concentrated in the major cancer centres.
Read the report (PDF)

Trust-level detail and live exploration are available to RxLens subscribers — see plans.

22 June 2026 Weight management GLP-1 Secondary care · London

Weight-management GLP-1s: how Mounjaro overtook Wegovy in London’s hospitals

A worked example of an RxLens market-intelligence report, covering the weight-management GLP-1 market across NHS acute Trusts in Greater London over the latest 12 months (April 2025 – March 2026): Wegovy (semaglutide; Novo Nordisk) versus Mounjaro (tirzepatide; Eli Lilly). It comes with an interactive dashboard you can explore.

  • In London the national order is reversed: Mounjaro already leads, with ~56% of patients to Wegovy’s ~44%.
  • And it is pulling away — Mounjaro grew ~62% in the latest six months and is dispensed in all 27 London Trusts that use these drugs (it leads in 25).
  • Wegovy’s volume is now concentrated in just two Trusts — St George’s and Imperial; Guy’s & St Thomas’ is the largest single Trust and is predominantly Mounjaro.
  • The market is highly concentrated (~£4.06m combined spend), and the report stress-tests the finding against the dose assumptions — Mounjaro stays ahead across the realistic range.
Read the report (PDF) Open the dashboard Slides (PPTX)

The dashboard above shows aggregate figures only. Underlying Trust-level data exports are available to RxLens subscribers — see plans.

22 June 2026 Monthly series All medicines · England

Monthly NHS Dispensing Snapshot — March 2026

Our regular snapshot of the latest national picture in NHS secondary-care medicines dispensing. Latest available data: March 2026.

  • NHS hospitals dispensed an indicative £2.31 billion of medicines in March 2026 — about £25.2 billion over the rolling 12 months.
  • 8,424 distinct products across 191 NHS Trusts; the Royal Free, Guy’s & St Thomas’ and Leeds lead on spend.
  • Biggest month-on-month movers, the top products by spend, and a full Trust league table — with the usual data-quality caveats.
Read the snapshot (PDF)

Published monthly. Trust-level detail and live exploration are available to RxLens subscribers — see plans.

About this data — please read

These reports are built from the Secondary Care Medicines Data (SCMD) published by NHS England / the NHS Business Services Authority under the Open Government Licence v3.0. They cover medicines dispensed by NHS hospital (secondary-care) pharmacies in England only — not primary care, private prescriptions, or the other UK nations.

The data is only as good as what each NHS organisation records, and the most recent months are provisional. Errors and anomalies do occur — mis-coded products, outlier quantities, duplicate or missing entries. In these free sample reports the data is presented broadly as published, with only the most obvious anomalies flagged. In our commissioned client reports we go further, identifying, cleaning and removing or correcting such errors as best we can before drawing conclusions.

Patient and treatment figures are modelled estimates derived from dispensing volumes and standard doses — they are directional, not a patient count. Cost figures are indicative only (list-price based) and do not reflect the confidential discounts NHS Trusts actually pay. RxLens is an independent service and is not affiliated with, endorsed by, or connected to NHS England or the NHSBSA.